Patents by Inventor Ellen Janine Beswick

Ellen Janine Beswick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of MK2 in the treatment of cancer
    Patent number: 10512651
    Abstract: The present invention relates to the discovery that MK2 is highly expressed in cancer tissue and the inhibition of MK2 using an MK2 inhibitor represents a viable approach to the treatment of cancer, including drug resistant cancers, metastatic cancers and recurrent cancers. MK2 inhibitors as described herein may be used alone or in combination with an at least one additional anti-cancer agent for the treatment of cancer.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: December 24, 2019
    Assignee: STC.UNM
    Inventor: Ellen Janine Beswick
  • INHIBITION OF MK2 IN THE TREATMENT OF CANCER
    Publication number: 20180221382
    Abstract: The present invention relates to the discovery that MK2 is highly expressed in cancer tissue and the inhibition of MK2 using an MK2 inhibitor represents a viable approach to the treatment of cancer, including drug resistant cancers, metastatic cancers and recurrent cancers. MK2 inhibitors as described herein may be used alone or in combination with an at least one additional anti-cancer agent for the treatment of cancer.
    Type: Application
    Filed: August 21, 2015
    Publication date: August 9, 2018
    Inventor: Ellen Janine Beswick
  • INHIBITION OF GRANULOCYTE COLONY STIMULATING FACTOR IN THE TREATMENT OF CANCER
    Publication number: 20160368980
    Abstract: The present invention relates to the discovery that granulocyte colony stimulating factor (G-CSF) as well as granulocyte colony stimulating factor receptor (G-CSFR) are highly expressed in cancer tissue and the inhibition of G-CSF using a G-CSF inhibitor, which term includes inhibitors of the G-CSF receptor, represents a viable approach to the treatment of cancer, including drug resistant cancers, metastatic cancers and recurrent cancers. G-CSF inhibitors as described herein may be used alone or in combination with an at least one additional anti-cancer agent for the treatment of cancer.
    Type: Application
    Filed: August 21, 2015
    Publication date: December 22, 2016
    Inventors: Katherine Theresa Morris, Ellen Janine Beswick